|
WO2010014250A1
|
|
Prediction of cancer therapy based on cathespin b levels
|
|
WO2010014249A1
|
|
Cancer therapy comprising estrogen inhibitors
|
|
US2008051603A1
|
|
Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
|
|
CA2656077A1
|
|
A process for the preparation of poly-alpha-glutamic acid and derivatives thereof
|
|
EP1967854A1
|
|
Method for determining the amount of conjugated taxane in polyglutamic acid-taxane conjugates
|
|
BRPI0620065A2
|
|
bisplatin complexes with antitumor activity
|
|
WO2007067498A1
|
|
Estrogen cancer therapy
|
|
ZA200707006B
|
|
Conjugates of biologically active proteins having a modified in vivo half-life
|
|
NZ556726A
|
|
Conjugates of biologically active proteins having a modified in vivo half-life
|
|
US2005148600A1
|
|
Methods for the treatment of obesity
|
|
US2005152979A1
|
|
Hydrophobic drug compositions containing reconstitution enhancer
|
|
US2004204386A1
|
|
Pyrimidines and uses thereof
|
|
US2004198728A1
|
|
Pyridines and uses thereof
|
|
US2004047835A1
|
|
Combinatorial drug therapy using polymer drug conjugates
|
|
US2003207901A1
|
|
Hydroxyl-containing compounds
|
|
US2003216289A1
|
|
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
|
US2004002526A1
|
|
Phospholipase D inhibitors and uses thereof
|
|
US2003153570A1
|
|
Aryl triazines as LPAAT-β inhibitors and uses thereof
|
|
US2003054977A1
|
|
Manufacture of polyglutamate-therapeutic agent conjugates
|
|
US2002150945A1
|
|
Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
|
